SUPPLEMENT SCIENCEInsights
Search

Search Insights

Try choline, nano-curcumin or probiotics.

    Ingredient guide · Ingredient reference

    Cisplatin and magnesium loss: an electrolyte problem needs monitoring

    Cisplatin treatment can contribute to low magnesium through impaired kidney handling. The effect is drug-specific and should be assessed by the oncology team rather than treated as a reason for every cancer patient to self-supplement.

    Read the evidence ↓

    Supplement Science Insights Editorial Team

    Published September 23, 2026

    Reduced reabsorption can increase losses

    The FDA-posted cisplatin information describes magnesium loss associated with renal tubular damage that interferes with reabsorption. Low calcium can also occur, and electrolyte monitoring is necessary. [1]

    This means low magnesium is not always explained by eating too little. In a treatment-related loss, increasing dietary intake may not fully address the underlying process. [1]

    Fit replacement to the treatment plan

    Report current supplements and follow the oncology team’s laboratory and replacement plan. The appropriate route and amount depend on the measured abnormality, kidney function and clinical situation. [1]

    The information does not establish that all chemotherapy drugs have the same effect or that routine retail magnesium prevents treatment complications. A low result needs interpretation in the context of the actual medicines being used. [1]

    Identify the loss before escalating intake

    Imagine a patient’s magnesium remains low during cisplatin treatment despite an adequate diet. The team may investigate renal losses and adjust monitored care; simply choosing a larger supplement does not explain or resolve the cause.

    Key distinctions — Cisplatin and magnesium loss
    DetailInterpretation
    CisplatinCan affect renal magnesium handling
    Dietary intakeOnly one part of balance
    ReplacementIndividual oncology plan
    Cisplatin and magnesium loss: an electrolyte problem needs monitoring — original article outline diagram
    Original editorial diagram of this article’s sections; no product photograph or clinical finding is depicted.

    Sources for this article

    1. CISplatin Injection Dear Healthcare Provider Letter
      Source consulted: 2026-09-17. This is a reference resource, not a claim that we conducted the studies or tested a product.